S&P 500

5.222,68

0,16%

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Hoth Therapeutics Inc (HOTH)
Hoth Therapeutics Inc (HOTH) Notícias

HOTH

Hoth Therapeutics (HOTH)

Hoth Therapeutics Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:HOTH

1 2 3 4 5 6 7 8 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
01/05/2024	09:00	PR Newswire (US)	Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024	NASDAQ:HOTH	Hoth Therapeutics Inc
27/03/2024	15:00	PR Newswire (US)	Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds	NASDAQ:HOTH	Hoth Therapeutics Inc
27/03/2024	09:27	PR Newswire (US)	Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment	NASDAQ:HOTH	Hoth Therapeutics Inc
19/03/2024	09:21	PR Newswire (US)	Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ	NASDAQ:HOTH	Hoth Therapeutics Inc
29/02/2024	10:38	PR Newswire (US)	Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio	NASDAQ:HOTH	Hoth Therapeutics Inc
26/02/2024	10:11	PR Newswire (US)	Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic	NASDAQ:HOTH	Hoth Therapeutics Inc
13/02/2024	13:45	PR Newswire (US)	Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024	NASDAQ:HOTH	Hoth Therapeutics Inc
18/01/2024	10:20	PR Newswire (US)	Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients	NASDAQ:HOTH	Hoth Therapeutics Inc
09/01/2024	17:03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HOTH	Hoth Therapeutics Inc
08/01/2024	19:01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HOTH	Hoth Therapeutics Inc
27/12/2023	10:21	PR Newswire (US)	Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami	NASDAQ:HOTH	Hoth Therapeutics Inc
05/12/2023	10:33	PR Newswire (US)	Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies	NASDAQ:HOTH	Hoth Therapeutics Inc
14/11/2023	10:37	PR Newswire (US)	Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT	NASDAQ:HOTH	Hoth Therapeutics Inc
13/11/2023	18:16	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:HOTH	Hoth Therapeutics Inc
10/11/2023	10:00	PR Newswire (US)	Hoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023	NASDAQ:HOTH	Hoth Therapeutics Inc
05/10/2023	11:03	PR Newswire (US)	Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug Discovery	NASDAQ:HOTH	Hoth Therapeutics Inc
02/10/2023	09:33	PR Newswire (US)	FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients	NASDAQ:HOTH	Hoth Therapeutics Inc
15/09/2023	15:38	PR Newswire (US)	Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules	NASDAQ:HOTH	Hoth Therapeutics Inc
14/09/2023	18:24	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:HOTH	Hoth Therapeutics Inc
13/09/2023	14:43	PR Newswire (US)	Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules	NASDAQ:HOTH	Hoth Therapeutics Inc
13/09/2023	09:16	PR Newswire (US)	Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia	NASDAQ:HOTH	Hoth Therapeutics Inc
11/09/2023	11:04	PR Newswire (US)	Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer Patients	NASDAQ:HOTH	Hoth Therapeutics Inc
06/09/2023	09:12	PR Newswire (US)	Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexa	NASDAQ:HOTH	Hoth Therapeutics Inc
21/08/2023	18:00	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:HOTH	Hoth Therapeutics Inc
09/08/2023	09:13	PR Newswire (US)	Hoth Therapeutics Announces Positive Preclinical End Point Results of HT-ALZ Treatment for Alzheimer's Disease	NASDAQ:HOTH	Hoth Therapeutics Inc
25/07/2023	09:12	PR Newswire (US)	Hoth Therapeutics Announces Major Milestone of First Patient Dosed in Phase 2a Clinical Trial	NASDAQ:HOTH	Hoth Therapeutics Inc
19/07/2023	09:02	PR Newswire (US)	Hoth Therapeutics Receives Protocol Approval for HT-001 Cancer Therapeutic	NASDAQ:HOTH	Hoth Therapeutics Inc
27/06/2023	17:22	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:HOTH	Hoth Therapeutics Inc
27/06/2023	17:21	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:HOTH	Hoth Therapeutics Inc
14/06/2023	09:12	PR Newswire (US)	Hoth Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial of HT-001 at Second Clinical Site	NASDAQ:HOTH	Hoth Therapeutics Inc